albuterol sulfate / Generic mfg. - LARVOL DELTA

Developing a Machine Learning Model That Uses Actively Measured Acoustic Resonance to Quantitate Response to Bronchodilators (ATS 2025) - " Participants (403 subjects: 123 COPD, 102 Asthma, 178 Healthy controls) wore the Sylvee active acoustic sensor on their chest as they performed a metronome breathing maneuver and underwent standard spirometry tests before and after nebulization using Albuterol sulfate... This study demonstrates the feasibility of using Sylvee sensor data and machine learning to identify patients' response to bronchoactive medications. This opens the possibility of using Sylvee as a non-invasive, affordable, and user-friendly alternative that can accurately monitor medication effects in a range of settings from the clinic to patients' homes. This will enable personalized treatment adjustments and enhance physicians' ability to deliver regular, real-time follow-up for patients."

Late-breaking abstract • Machine learning • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Estimating the Greenhouse Gas Emissions of Outpatient Inhalers at Stanford Medicine (ATS 2025) - "The three most prescribed inhalers were albuterol sulfate, budesonide-formoterol, and fluticasone propionate; these metered-dose inhalers alone accounted for 92% of inhaler prescriptions and 90% of inhaler-related emissions over the study period. Metered-dose inhalers accounted for the majority of inhaler prescription orders and nearly all of the inhaler-related greenhouse gas emissions from selected Stanford Medicine outpatient clinics. The carbon equivalent emissions associated with metered-dose inhaler prescriptions at these clinics were equivalent to driving an average gasoline-powered passenger vehicle for 335,218 miles. While the increased use of propellant-free dry powder and soft mist inhalers may reduce the carbon footprint of respiratory care, individual prescribing decisions must be weighed against clinical and cost considerations."

Clinical • Immunology

A Performance Comparison of Three Nebulizers Delivering a Combination of Ipratropium/Albuterol Inhalation Solution (ATS 2025) - "This study aimed to compare three nebulizers by assessing in-vitro Fine Droplet Mass (FDM<4.7μm) and aerosol characteristics of a combination of ipratropium/albuterol over time. AeroEclipse® II BAN® Nebulizer (AE), AirLife™ Misty Fast™ (MF) and Circulaire® II (CA) devices (n=5) were filled with 1 DuoNeb® (ipratropium bromide 0.5 mg/ albuterol sulfate 3.0 mg) vial. All nebulizers showed consistent incremental increases in delivered doses of each medication minute by minute. The AeroEclipse® BAN® Nebulizer provided the highest FDM in substantially less time compared to the other nebulizers tested making this a reasonable option for recognizing a time savings by offering a timed treatment option. The effectiveness of small volume nebulizers can vary greatly, making it crucial to choose the right one to optimize drug delivery and achieve the best therapeutic outcomes."

Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Prediction of Myasthenia Gravis (MG) Crisis Events by a Machine Learning (ML) Algorithm (ISPOR 2025) - "A regularized logistic regression model was applied to the identified variables using the H2O AutoML package. Patients with MG crises at year 1 (n=332) were significantly (P<0.05) more likely than those without MG crises at year 1 (n=7277) to be older at MG index date (mean±SD: 61.5±14.5 vs 57.1±14.8 years, respectively), have higher rates of comorbidities/symptoms (eg, shortness of breath [21.1% vs 9.3%], dysphagia [20.0% vs 9.0%]), and have certain prescription claims (eg, albuterol sulfate [11.7% vs 4.9%], amlodipine besylate [11.4% vs 5.6%]). This novel analysis using a ML algorithm identified several key patient-relevant characteristics, disease symptoms, and comorbidities that are risk factors for experiencing an MG crisis, and these results may help inform future treatment strategies to reduce the risk of MG crises."

Machine learning • CNS Disorders • Cough • Gastrointestinal Disorder • Myasthenia Gravis • Pulmonary Disease • Respiratory Diseases

Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Nemours Children's Clinic

New P3 trial • Pulmonary Disease • Respiratory Diseases

Impact of normal, obstructive, and restrictive breathing patterns on aerosol drug delivery with jet and mesh nebulizers in simulated spontaneously breathing adults. (PubMed, Can J Respir Ther) - "Albuterol sulfate (2.5 mg/3 mL) was delivered with jet (MistyMax 10) and mesh nebulizers (Aerogen Ultra)...Aerosol delivery with the mesh nebulizer was up to 3-fold more than the jet nebulizer regardless of the breathing pattern tested in this study (p < 0.05). This study highlights the necessity for tailored aerosol therapy strategies to optimize drug delivery in patients with different respiratory conditions.."

Journal

Quantification of Health Care Worker Model to Secondhand Exposure of Aerosols During Nebulization Treatment. (PubMed, Respir Care) - "A jet nebulizer delivered albuterol sulfate (15 mg/3 mL) in 2 consecutive sessions, totaling 30 mg in 30 min... The HCW models were exposed to fugitive aerosol particles during nebulization, with inhaled doses from 0.1% to 0.3%. Although exposure was low, further in vivo studies are needed to assess potential health risks with prolonged exposure."

Journal

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2196 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (clinicaltrials.gov) - P3 | N=2196 | Active, not recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Inhaled albuterol rapidly decreases whole blood potassium and increases plasma insulin concentrations, with peak effects 30 minutes after administration in cats. (PubMed, J Am Vet Med Assoc) - "In a prospective, randomized study between June 2023 and January 2024, 20 client-owned cats received albuterol sulfate at a low dose (90 µg) or high dose (360 µg)...Albuterol rapidly decreases blood potassium concentrations in part by stimulating endogenous insulin secretion in cats without dose-dependent effects or clinically meaningful changes in HR or glucose concentrations. Inhaled albuterol may be useful to decrease blood potassium concentrations in hyperkalemic cats."

Journal

Aerosol Delivery to Simulated Spontaneously Breathing Tracheostomized Adult Patients With Heated Humidified High Flow Oxygenation. (PubMed, Respir Care) - "Albuterol sulfate (2.5 mg/3 mL) was aerosolized via a vibrating mesh nebulizer in-line with HHHF (Airvo2)... During aerosol delivery via in-line placement of vibrating mesh nebulizer with HHHF in a tracheostomized model, the inhaled dose increased as flow decreased. Distal nebulizer placement resulted in higher inhaled doses than proximal placement with the tracheostomy adapter at all flows and with the tracheostomy collar at 15 L/min."

Journal

Optimization of Albuterol Delivery via Anesthesia Bag in Pediatric Critical Care. (PubMed, Pharmaceutics) - " Using a simulated pediatric lung model (ASL 5000) with the semi-open Mapleson anesthesia circuit, 2.5 mg/3 mL of albuterol sulfate solution was nebulized to a viral/bacterial filter (Respiguard 202)... Modifying the anesthesia breathing circuit significantly improved aerosol drug delivery efficiency. Our findings suggest that current clinical practices for nebulized drug delivery are inefficient and can be markedly improved with simple adjustments in nebulizer positioning and gas flow within the circuit."

Journal • Anesthesia • Critical care • Fatigue • Pediatrics

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma (clinicaltrials.gov) - P=N/A | N=148 | Recruiting | Sponsor: Intech Biopharm Ltd. | Trial completion date: Apr 2024 ➔ Jun 2025 | Trial primary completion date: Mar 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Breathing Easy in Maricopa County, Arizona: Empowering K-12 Schools With a Novel Nurse Coaching Model to Facilitate Implementation of a County-Wide School-Based Stock Albuterol Inhaler Program. (PubMed, J Sch Nurs) - "To reduce chronic school absenteeism and morbidity and mortality among school-aged children, the prompt administration of albuterol sulfate in schools remains vital...Most events (78%) were compliant with the protocol for administering the stock inhaler to a student. These findings suggest that implementing a practice facilitation model is feasible and important for enhancing fidelity to program requirements."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs. (PubMed, ACS Pharmacol Transl Sci) - "To understand how the characterized ALI quality attributes influenced the absorption of inhaled drugs through the epithelial-endothelial barrier, we measured the permeability and epithelial intracellular concentrations of albuterol sulfate (AL), formoterol fumarate (FO), and fluticasone furoate (FL). Due to its high lipophilicity, FL showed a higher intracellular concentration (17.4%) compared to AL and FO, but also a 73.1% loss of the compound over 3 h due to nonspecific binding, with a P app as low as 1.3 × 10-7 cm/s. While the model exhibited physiologically relevant properties, its utility in estimating the permeability of inhaled drugs may be drug-specific, warranting further optimization and study."

Journal

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (clinicaltrials.gov) - P3 | N=724 | Recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison Between Various Jet Nebulizers Designed to Provide a Shorter Aerosol Treatment Time (AARC 2024) - "Each nebulizer was loaded with 3 mL of 2.5 mg albuterol sulfate solution with the gas flow set to deliver 8 L/min... All nebulizers tested were fast nebulizers. Device output and medication delivery to the distal airways must be considered when selecting an aerosol generator along with time. Poor aerosol delivery could require more frequent treatments which would negate the benefit of using a higher output nebulizer."

Respiratory Diseases

An Evaluation of Three Styles of Jet Nebulizers; Standard Jet, Breath Enhanced, and Breath Actuated/Breath Enhanced (AARC 2024) - "Each nebulizer was loaded with 3 mL of 2.5 mg albuterol sulfate solution with the gas flow set to deliver 8 L/min... Being able to provide adequate medication delivery over a shorter period is desirable, first to elicit relief for the patient, but also to promote efficiency in workflow. Even though the AeroEclipse II still had medication left to nebulize, performing a 4 min timed dose still allowed for a 33% increase in respirable dose over TurboMist and a 41% increase over Misty Max 10 allowing the user to get more medication into the distal airways in a short period of time. Table 1: Fine droplet mass by nebulizer over four minutes Figure 1: Fraction of delivered output mass with particles < 4.7 μm."

Respiratory Diseases

In Vitro Evaluation of Aerosol Delivery via a New High-Flow Nasal Cannula Device in Adult, Toddler, and Neonate (AARC 2024) - " Albuterol sulfate (2.5mg/3 mL) was administered using a vibrating mesh nebulizer (VMN) and delivered through two HFNC devices (Inspired O2 and Airvo 2)... In-line nebulization using the Inspired O2 device was as effective as Airvo 2. Both HFNC devices with low flows generated higher aerosol delivery than conventional aerosol delivery through an aerosol mask. Figure1."

Preclinical • Respiratory Diseases

Healthcare Worker Inhalation Exposure of Fugitive Aerosols During Nebulization Treatment: In Vitro Quantification (AARC 2024) - "Albuterol sulfate (15 mg/3 mL) was nebulized via a jet nebulizer in two consecutive sessions, totaling 30 mg in 30 min... Exposure to fugitive aerosol particles during nebulization treatment was consistent across all tested interfaces and patient-HCW distances, with inhaled doses ranging from 0.1% to 0.3%. Further studies are required to assess the potential risk this level of exposure to secondhand fugitive aerosols represents to HCWs. Figure 1: Experimental setup for quantifying healthcare worker (HCW) inhalation exposure to fugitive aerosols during nebulization treatment."

Preclinical • Respiratory Diseases

Impact of nebulization versus metered-dose inhaler utilization on viral particle dispersion in patients with COVID-19. (PubMed, J Infect Prev) - "Adults infected with COVID-19 were enrolled and received a single dose of albuterol sulfate nebulized solution (2.5 mg/3 mL via breath-actuated nebulizer with filtered mouthpiece) or albuterol sulfate hydrofluoroalkane inhalation aerosol (90 µg/actuation; two puffs via MDI with spacer) in a randomized crossover sequence. In this first prospective trial evaluating viral load distribution following use of nebulizer versus MDI in hospitalized patients with COVID-19, low environmental contamination was found regardless of administration method. Findings support the use of either device when needed to treat patients with COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (clinicaltrials.gov) - P3 | N=724 | Not yet recruiting | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting ➔ Completed | N=22 ➔ 30

Enrollment change • Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

UNIQUE CT SCAN PRESENTATION OF METASTATIC PANCREATIC CANCER WITH PULMONARY INVOLVEMENT (CHEST 2024) - "The patient was initiated on scheduled budesonide-formoterol and albuterol-sulfate as needed... In conclusion, this case report highlights the rare CT findings of atypical alveolar pattern associated with lung metastasis from pancreatic adenocarcinoma."

Metastases • Cough • Diabetes • Gastrointestinal Cancer • Genetic Disorders • Hepatology • Metabolic Disorders • Obesity • Oncology • Palliative care • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Pancreatitis • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor

MYCOBACTERIUM CHELONAE-ASSOCIATED BRONCHIECTASIS IN AN IMMUNOCOMPETENT HOST: A RARE PRESENTATION (CHEST 2024) - "Consequently, she was initiated on a bronchial hygiene regimen including albuterol HFA, 7% hypertonic saline, Aerobika, huff cough, and saline sinus rinses with distilled water, without starting an antibiotic regimen after a thorough discussion of risks versus benefits. The isolation of Mycobacterium chelonae in an immunocompetent host represents a rare occurrence, particularly in the context of bronchiectasis without predisposing factors. It underscores the critical importance of considering even the most uncommon pathogens in patients with atypical respiratory presentations. The successful management of this case, focusing on bronchial hygiene without the necessity for antibiotic therapy, further illustrates the importance of a tailored approach in the treatment of rare infectious diseases."

Alpha-1 Antitrypsin Deficiency • Bronchiectasis • Cough • Cystic Fibrosis • Genetic Disorders • Hepatology • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • DNAH9 • FLCN